EMERGENT BIOSOLUTIONS INC. Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share
EMERGENT BIOSOLUTIONS INC. (EBS) reported Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2017-03-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for the quarter ending 2016-12-31 was $0.13.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2018 was $0.00.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2017 was $0.00.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2016 was -$0.27.
- EMERGENT BIOSOLUTIONS INC. discontinued operation, income (loss) from discontinued operation, net of tax, per basic share for fiscal 2015 was -$0.74.
| Period end | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 3 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 6 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 9 month | Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-22 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 | |||
| 2017-09-30 | $0.00 10-Q · filed 2017-11-03 | $0.00 10-Q · filed 2017-11-03 | ||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | |||
| 2016-12-31 | $0.13 10-K · filed 2018-02-23 | -$0.27 10-K · filed 2019-02-22 | ||
| 2016-09-30 | $0.02 10-K · filed 2018-02-23 | -$0.40 10-Q · filed 2017-11-03 | ||
| 2016-06-30 | -$0.22 10-K · filed 2018-02-23 | -$0.42 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | -$0.20 10-K · filed 2018-02-23 | |||
| 2015-12-31 | -$0.23 10-K · filed 2017-02-28 | -$0.74 10-K · filed 2018-02-23 | ||
| 2015-09-30 | -$0.14 10-K · filed 2017-02-28 | -$0.51 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | -$0.22 10-K · filed 2017-02-28 | |||
| 2015-03-31 | -$0.15 10-K · filed 2017-02-28 | |||
| 2014-12-31 | -$0.47 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |